The New Standard Adjuvant Treatment for High-risk Stage 1 Nonseminoma: Reducing the Treatment Burden and Maximizing Long-term Survival

In this issue of European Urology, Cullen et al [1] present results from the 111 study evaluating adjuvant chemotherapy consisting of one cycle of bleomycin, etoposide and cisplatin (BEP) in high-risk, stage 1 nonseminomatous germ cell tumor of the testis (NSGCT). These results add to the growing body of data on the efficacy of one cycle of adjuvant BEP in NSGCT. To date, three large prospective…

Read the full article here

Related Articles